Iptacopan (Synonyms: LNP023) CAS No.: 1644670-37-0

Iptacopan (Synonyms: LNP023) CAS No.: 1644670-37-0

Chemical Structure : Iptacopan (Synonyms: LNP023)
CAS No.: 1644670-37-0

Description

Chemical Structure : Iptacopan (Synonyms: LNP023)

CAS No.: 1644670-37-0

product-600-600

 

Iptacopan (Synonyms: LNP023)

Catalog No.: URK-V2532 Only Used For Lab.

Iptacopan, also known as Vebicorstat, is a novel oral inhibitor of factor B, a key component of the alternative complement pathway.

 

Biological Activity

Iptacopan, also known as Vebicorstat, is a novel oral inhibitor of factor B, a key component of the alternative complement pathway. It is indicated for the treatment of hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) and is currently in late-stage clinical development.
Iptacopan works by blocking the activation of factor B and subsequent formation of the C3 convertase complex, which leads to the downstream effects of the alternative complement pathway. By inhibiting this pathway, Iptacopan has been shown to decrease the risk of thrombotic microangiopathy, a potentially life-threatening condition often seen in patients undergoing hematopoietic stem cell transplantation.
Studies have shown promising results for the use of Iptacopan in the treatment of HSCT-TMA, with no significant adverse effects reported. In a phase 2 trial, Iptacopan treatment led to a complete response in 43% of patients with HSCT-TMA, compared to 0% in the placebo group. Additionally, Iptacopan has also been studied in other complement-mediated diseases such as paroxysmal nocturnal hemoglobinuria and C3 glomerulopathy.

 

Physicochemical Properties

M.Wt

422.52

Formula

C25H30N2O4

CAS No.

1644670-37-0

Appearance

Solid

Storage

Solide Powder

-20 °C 3years;

4°C 2years

In Solvent

-80°C 6 Months

-20°C 1 Months

Solubility

 

Chemical Name

 

 

References

1. Ricklin D, Reis ES, Lambris JD. Complement in disease: a defence system turning offensive. Nat Rev Nephrol. 2016;12(7):383-401.

 

2. Hillmen P. Understanding complement mediated hemolysis and complement inhibition. Blood Rev. 2013;27(4):213-219.

 

3. Jodele S, Dandoy CE, Lane A, et al. Complement blockade for HSCT-associated TMA: lessons learned from a large cohort treated with eculizumab. Blood. 2020;135(12):1049-1057.

 

4. Cho BS, Yahng SA, Lee SE, et al. Efficacy of eculizumab and comparison of prognostic factors in patients with hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Biol Blood Marrow Transplant. 2013;19(9):1268-1272.

 

product-80-80

URK-V2532_COA

product-80-80

URk-V2532_SDS

product-80-80

URK-V2532_TDS

Hot Tags: Iptacopan (Synonyms: LNP023) CAS No.: 1644670-37-0, China Iptacopan (Synonyms: LNP023) CAS No.: 1644670-37-0, epigenetic library for epigenetic analysis of epigenetic evolution, epigenetic library for epigenetic phenotype, agonists for endocytosis, inhibitors for drug delivery, agonists for cell proliferation, epigenetic library for epigenetic regulation of cell migration

You Might Also Like

Shopping Bags